Deep learning-based analysis reveals patient-level cancer therapy trajectories using single-cell PBMC chromatin images
Abstract
Peripheral blood mononuclear cells (PBMCs) profiled in different data modalities have emerged as diagnostic and prognostic biomarkers for cancer. Here we demonstrate that PBMC chromatin images contain sufficient information to track patients’ trajectories during and after radiation therapy. We collected images from 150 patients across a variety of cancer types including Central Nervous System (CNS) cancer, Head & Neck cancer, Chordoma and Chondrosarcoma, Sarcoma, and Lymphoma, and adapted a multiple instance learning-based framework, which effectively enhanced the patient-level classification and interpretation of images from diverse samples compared to simpler cell-level neural network-based classifiers. We found that patients whose PBMCs returned to a state more similar to healthy after the therapy had more favorable outcomes. Moreover, our framework could indicate whether Head & Neck cancer patients’ PBMCs would likely return to a state similar to healthy after radiation therapy using solely chromatin images from before the treatment. These findings motivate further study of PBMC chromatin images to be used as a non-invasive, easily obtained, and inexpensive biomarker for cancer detection, treatment monitoring, and treatment response prediction.
Related
- Circulating chromatin reveals effects of disease-associated variants on gene regulation
- Induction of hysteretic chromatin states by CRISPRa reveals locus-specific encoding of transcriptional memory
- Multiomics analysis reveals the enhancer landscapes and 3D chromatin architecture in esophageal squamous cell carcinoma
- Genetic integration reveals causal effects of chromatin accessibility on nucleosome positioning across diverse muscle cells
- Quantitative FLIM-FRET Microscopy to Monitor Nanoscale Chromatin Compaction In Vivo Reveals Structural Roles of Condensin Complexes
BibTeX
@article{schluter2026deep,
title = {{Deep learning-based analysis reveals patient-level cancer therapy trajectories using single-cell PBMC chromatin images}},
author = {Hannah M. Schlüter and Trinadha Rao Sornapudi and Dominic Leiser and Sandra Koller and Zeynep Karavelioglu and Caroline Uhler and G. V. Shivashankar},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-74792-x},
url = {https://www.nature.com/articles/s41598-026-74792-x},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Deep learning-based analysis reveals patient-level cancer therapy trajectories using single-cell PBMC chromatin images
AU - Hannah M. Schlüter
AU - Trinadha Rao Sornapudi
AU - Dominic Leiser
AU - Sandra Koller
AU - Zeynep Karavelioglu
AU - Caroline Uhler
AU - G. V. Shivashankar
PY - 2026
DA - 2026/10/01
JO - Scientific Reports
DO - 10.1038/s41598-026-74792-x
UR - https://www.nature.com/articles/s41598-026-74792-x
AB - Peripheral blood mononuclear cells (PBMCs) profiled in different data modalities have emerged as diagnostic and prognostic biomarkers for cancer. Here we demonstrate that PBMC chromatin images contain sufficient information to track patients’ trajectories during and after radiation therapy. We collected images from 150 patients across a variety of cancer types including Central Nervous System (CNS) cancer, Head & Neck cancer, Chordoma and Chondrosarcoma, Sarcoma, and Lymphoma, and adapted a multiple instance learning-based framework, which effectively enhanced the patient-level classification and interpretation of images from diverse samples compared to simpler cell-level neural network-based classifiers. We found that patients whose PBMCs returned to a state more similar to healthy after the therapy had more favorable outcomes. Moreover, our framework could indicate whether Head & Neck cancer patients’ PBMCs would likely return to a state similar to healthy after radiation therapy using solely chromatin images from before the treatment. These findings motivate further study of PBMC chromatin images to be used as a non-invasive, easily obtained, and inexpensive biomarker for cancer detection, treatment monitoring, and treatment response prediction.
SN - 2045-2322
ER -